Business
Health Logic Interactive Receives Letter of Support from the Chief of the Division of Nephrology at Johns Hopkins University School of Medicine
Health Logic Interactive Receives Letter of Support from the Chief of the Division of Nep...
About this update from Health Logic Interactive Inc
[{"type":"text","content":"\n \n \n \n Health Logic Interactive Receives Letter of Support from the Chief of the Division of Nephrology at Johns Hopkins University School of Medicine\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n \n TSXV: CHIP.H\n \n \n \n \n \n \n CALGARY, AB,\n \n May 26, 2021\n \n /CNW/ -\n \n Health Logic Interactive Inc\n \n . (\"\n \n Health Logic\n \n \" or the \"\n \n Company\n \n \") (TSXV: CHIP.H)(OTCPK: CHYPF), is pleased to announce its wholly-owned operating subsidiary,\n \n My Health Logic\n \n \n Inc.\n \n (\"\n \n My Health Logic\n \n \"), has received a letter of support on the Company's chronic kidney disease (CKD) technology from nephrologist\n \n Chirag R. Parikh\n \n , MD, PhD Director, Division of Nephrology at\n \n Johns Hopkins University School of Medicine\n \n . This letter supports the Company's belief that its lab-on-chip device for the early detection of CKD has the potential to address a large and unmet need of patients who have, or are at risk for developing, CKD.\n \n \n \n \n \n \n \n \n \n In his support letter, Dr. Parikh stated, \"As the Chief of the Division of Nephrology and the Ronald Peterson Professor of Medicine at the\n \n Johns Hopkins University School of Medicine\n \n , I have the responsibility to manage our division's clinical and research efforts as well as coordinate care delivery for the at-risk population in\n \n Baltimore\n \n and surrounding areas. Many patients at the highest risk for CKD do not have access to screening, and there is no convenient method for at home/easily accessible devices for patients who require routine monitoring of urine albumin for follow up of their glomerular disease.  Your proposed device and health delivery platform has an opportunity to transform this space by making screening feasible at every health encounter and potentially at home. \"\n \n \n When asked about this support letter from Dr. Parikh, Dr. Tangri, a member of the Company's scientific development team and one of the co-founders of the device, stated that \"according to ...